FDA delays feedback on Novo's Victoza

Novo Nordisk said today that the FDA has delayed feedback on its much-anticipated diabetes drug Victoza (liraglutide) until the fourth quarter of this year. The company had predicted a positive response from the agency by this month. "Novo Nordisk continues the constructive dialog with the FDA regarding the regulatory process for liraglutide," the company said in a statement. Novo said the feedback delay will not impact company's financial results for 2009. The drug received EMEA approval in June and is already being marketed in Europe.

- take a look at Novo's release
- read the Reuters write-up

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.